B Group Inc. Takes $1.67 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

B Group Inc. bought a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 965,556 shares of the company's stock, valued at approximately $1,670,000. Taysha Gene Therapies comprises about 1.0% of B Group Inc.'s portfolio, making the stock its 10th largest position. B Group Inc. owned approximately 0.47% of Taysha Gene Therapies as of its most recent SEC filing.

Several other large investors have also bought and sold shares of TSHA. Geode Capital Management LLC increased its position in Taysha Gene Therapies by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after buying an additional 9,591 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after acquiring an additional 11,390 shares during the period. Privium Fund Management B.V. lifted its holdings in Taysha Gene Therapies by 12.4% during the fourth quarter. Privium Fund Management B.V. now owns 134,900 shares of the company's stock valued at $233,000 after purchasing an additional 14,900 shares in the last quarter. Cibc World Markets Corp purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $28,000. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $31,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on TSHA shares. Needham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Chardan Capital restated a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $6.63.

Taysha Gene Therapies Price Performance

Shares of TSHA stock traded up $0.04 on Wednesday, reaching $1.82. The company's stock had a trading volume of 3,992,602 shares, compared to its average volume of 2,701,241. The stock's fifty day simple moving average is $1.54 and its 200-day simple moving average is $1.80. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $4.32. The company has a market capitalization of $373.20 million, a price-to-earnings ratio of 2.89 and a beta of 0.96. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The firm had revenue of $2.02 million for the quarter, compared to analysts' expectations of $2.05 million. Analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.